Plaugher D, Childress A, Gosser C, Esoe D, Naughton K, Hao Z
Cancer Lett. 2024; 605:217281.
PMID: 39369769
PMC: 11560632.
DOI: 10.1016/j.canlet.2024.217281.
Tchelougou D, Malaquin N, B Cardin G, Desmul J, Turcotte S, Rodier F
Front Cell Dev Biol. 2024; 12:1368711.
PMID: 38946802
PMC: 11211604.
DOI: 10.3389/fcell.2024.1368711.
Mabrouk N, Racoeur C, Shan J, Massot A, Ghione S, Privat M
Cancers (Basel). 2023; 15(12).
PMID: 37370739
PMC: 10296121.
DOI: 10.3390/cancers15123129.
Jiang N, Malone M, Chizari S
Immunol Rev. 2023; 316(1):120-135.
PMID: 37209375
PMC: 10524458.
DOI: 10.1111/imr.13217.
Modur V, Muhammad B, Yang J, Zheng Y, Komurov K, Guo F
Cell Rep. 2023; 42(4):112364.
PMID: 37043352
PMC: 10562518.
DOI: 10.1016/j.celrep.2023.112364.
Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells.
Amaro A, Reggiani F, Fenoglio D, Gangemi R, Tosi A, Parodi A
J Exp Clin Cancer Res. 2023; 42(1):67.
PMID: 36934257
PMC: 10024396.
DOI: 10.1186/s13046-023-02628-x.
Adoptive NK Cell Therapy: A Promising Treatment Prospect for Metastatic Melanoma.
van Vliet A, Georgoudaki A, Raimo M, de Gruijl T, Spanholtz J
Cancers (Basel). 2021; 13(18).
PMID: 34572949
PMC: 8471577.
DOI: 10.3390/cancers13184722.
Prognostic and therapeutic TILs of cervical cancer-Current advances and future perspectives.
Tang Y, Zhang A, Chen G, Wu Y, Gu W
Mol Ther Oncolytics. 2021; 22:410-430.
PMID: 34553029
PMC: 8430272.
DOI: 10.1016/j.omto.2021.07.006.
Building on Synthetic Immunology and T Cell Engineering: A Brief Journey Through the History of Chimeric Antigen Receptors.
Abken H
Hum Gene Ther. 2021; 32(19-20):1011-1028.
PMID: 34405686
PMC: 10112879.
DOI: 10.1089/hum.2021.165.
CCL27 Signaling in the Tumor Microenvironment.
Martinez-Rodriguez M, Monteagudo C
Adv Exp Med Biol. 2021; 1302:113-132.
PMID: 34286445
DOI: 10.1007/978-3-030-62658-7_9.
Immersion in the search for effective cancer immunotherapies.
Rosenberg S
Mol Med. 2021; 27(1):63.
PMID: 34134616
PMC: 8210396.
DOI: 10.1186/s10020-021-00321-3.
USP22 deficiency in melanoma mediates resistance to T cells through IFNγ-JAK1-STAT1 signal axis.
Li M, Xu Y, Liang J, Lin H, Qi X, Li F
Mol Ther. 2021; 29(6):2108-2120.
PMID: 33601053
PMC: 8178440.
DOI: 10.1016/j.ymthe.2021.02.018.
CD29 identifies IFN-γ-producing human CD8 T cells with an increased cytotoxic potential.
Nicolet B, Guislain A, van Alphen F, Gomez-Eerland R, Schumacher T, van den Biggelaar M
Proc Natl Acad Sci U S A. 2020; 117(12):6686-6696.
PMID: 32161126
PMC: 7104308.
DOI: 10.1073/pnas.1913940117.
Human T cells employ conserved AU-rich elements to fine-tune IFN-γ production.
Freen-van Heeren J, Popovic B, Guislain A, Wolkers M
Eur J Immunol. 2020; 50(7):949-958.
PMID: 32112565
PMC: 7384093.
DOI: 10.1002/eji.201948458.
Bi- and tri-valent T cell engagers deplete tumour-associated macrophages in cancer patient samples.
Scott E, Jacobus E, Lyons B, Frost S, Freedman J, Dyer A
J Immunother Cancer. 2019; 7(1):320.
PMID: 31753017
PMC: 6873687.
DOI: 10.1186/s40425-019-0807-6.
Antisense targeting of CD47 enhances human cytotoxic T-cell activity and increases survival of mice bearing B16 melanoma when combined with anti-CTLA4 and tumor irradiation.
Schwartz A, Nath P, Allgauer M, Lessey-Morillon E, Sipes J, Ridnour L
Cancer Immunol Immunother. 2019; 68(11):1805-1817.
PMID: 31628526
PMC: 7416244.
DOI: 10.1007/s00262-019-02397-7.
STING Signaling in Melanoma Cells Shapes Antigenicity and Can Promote Antitumor T-cell Activity.
Falahat R, Perez-Villarroel P, Mailloux A, Zhu G, Pilon-Thomas S, Barber G
Cancer Immunol Res. 2019; 7(11):1837-1848.
PMID: 31462408
PMC: 6825582.
DOI: 10.1158/2326-6066.CIR-19-0229.
Vitamin D Controls Tumor Growth and CD8+ T Cell Infiltration in Breast Cancer.
Karkeni E, Morin S, Bou Tayeh B, Goubard A, Josselin E, Castellano R
Front Immunol. 2019; 10:1307.
PMID: 31244851
PMC: 6563618.
DOI: 10.3389/fimmu.2019.01307.
Treatment of metastatic non-small cell lung cancer with NY-ESO-1 specific TCR engineered-T cells in a phase I clinical trial: A case report.
Xia Y, Tian X, Wang J, Qiao D, Liu X, Xiao L
Oncol Lett. 2018; 16(6):6998-7007.
PMID: 30546433
PMC: 6256329.
DOI: 10.3892/ol.2018.9534.
Human breast tumor-infiltrating CD8 T cells retain polyfunctionality despite PD-1 expression.
Egelston C, Avalos C, Tu T, Simons D, Jimenez G, Jung J
Nat Commun. 2018; 9(1):4297.
PMID: 30327458
PMC: 6191461.
DOI: 10.1038/s41467-018-06653-9.